Retatrutide and Pregnancy: What Triple Agonism Means for Fertility and Safety

Retatrutide (LY3437943) is an investigational triple-agonist drug that activates three receptors: GLP-1, GIP, and glucagon. It has not been approved by any regulatory agency, and there is no published human data on retatrutide use during pregnancy.

This matters more than it might seem. Semaglutide and tirzepatide each raise one or two receptor-level concerns for pregnancy. Retatrutide raises three — because each of the receptors it targets has been independently linked to reproductive or fetal development pathways in preclinical research.

This page summarizes what the published research shows for each receptor, how retatrutide compares to approved GLP-1 drugs on washout timing, and what practical considerations exist for anyone planning pregnancy while on or considering a GLP-1-class drug.

This page is not medical advice. Retatrutide is not FDA-approved and no prescribing guidance exists. If you are pregnant, planning pregnancy, or breastfeeding, consult your healthcare provider before making any decisions about GLP-1 medications. The information below is drawn from animal studies, observational human data on other GLP-1 drugs, and receptor pharmacology — not from direct evidence on retatrutide in human pregnancy.

Why Triple Agonism Creates Unique Pregnancy Concerns

Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 and GIP). Retatrutide activates all three — GLP-1, GIP, and glucagon. Each of these receptors has been linked to reproductive biology in preclinical research, meaning retatrutide introduces concerns that no other obesity drug on the market does.

This does not mean retatrutide is necessarily more dangerous during pregnancy than other GLP-1 drugs. It means there are more unknowns — and the unknowns span different biological systems.

GLP-1 Receptor: The Known Class-Level Risk

All GLP-1 receptor agonists share this concern. In animal reproduction studies, semaglutide caused embryofetal mortality, structural abnormalities, and growth alterations in rats at clinically relevant exposures. In rabbits and cynomolgus monkeys, semaglutide caused early pregnancy losses or structural abnormalities. Tirzepatide showed fetal growth reductions and skeletal abnormalities in rats during organogenesis at clinically relevant exposures.

The FDA labels for both Ozempic/Wegovy and Mounjaro/Zepbound carry pregnancy warnings based on these animal findings. No GLP-1 receptor agonist is approved for use during pregnancy.

In humans, the data is more reassuring but limited. A multinational cohort study published in JAMA Internal Medicine (2024) examined over 50,000 pregnancies in women with type 2 diabetes and found no greater risk of major congenital malformations with periconceptional GLP-1 receptor agonist use compared to insulin. A separate 2024 multicenter observational study of 168 pregnancies with first-trimester GLP-1 receptor agonist exposure found a 2.6% major birth defect rate — comparable to background rates. These studies are reassuring but small, and neither included retatrutide.

GIP Receptor: Ovarian Function and Progesterone

This is where retatrutide diverges from semaglutide. GIP receptors are expressed in female reproductive tissue — including the ovaries, pituitary, and uterine horn. Research published in the International Journal of Molecular Sciences (2022) demonstrated that:

• GIP suppresses progesterone synthesis in rat granulosa cells in the presence of follicle-stimulating hormone (FSH), and GIP's suppressive effect was more potent than that of GLP-1
• GIPR knockout mice showed 50% reduced fertility — only half of female GIPR-deficient mice produced litters across three breeding cycles compared to wild-type controls
• Estrous cycling was significantly disrupted in GIPR-null females, with each completing only one full cycle over a 20-day monitoring period versus multiple cycles in controls
• Litter sizes were substantially reduced in GIPR-deficient mice

A 2024 European Congress of Endocrinology presentation confirmed GIP receptor expression in human cumulus granulosa cells — the cells that directly surround and support the developing egg.

Progesterone is critical for implantation and early pregnancy maintenance. A drug that agonizes the GIP receptor could theoretically suppress progesterone production in granulosa cells, though whether this occurs at clinical doses in humans has not been studied.

Glucagon Receptor: Placental Development and Fetal Survival

This is unique to retatrutide among the current generation of obesity drugs. Research published in the American Journal of Physiology — Endocrinology and Metabolism (2012) found that glucagon receptor knockout (Gcgr−/−) mice exhibited:

• Significant fetal demise — Gcgr−/− dams produced only 3.6 live pups per litter versus 8.5 in wild-type controls, with 4.6 resorption sites versus 1.3 in controls
• Severe placental abnormalities in 50% of placentas from live fetuses — including mineralization, fibrinoid necrosis, narrowing of vascular channels, and trophoblast hyperplasia
• Downregulation of IGF-1 and IGF-1 receptor expression in the placenta, which are critical for placental nutrient transport

The mechanism appeared to be maternal metabolic disruption (hypoglycemia and hyperglucagonemia) rather than direct ovarian axis interference. This is an important distinction: retatrutide activates the glucagon receptor rather than knocking it out, so the effects would not be identical. However, the finding that glucagon signaling is important for placental development and fetal survival introduces a concern that does not exist for semaglutide or tirzepatide.

Washout Periods: How Long Before Pregnancy?

A "washout period" is the time a drug needs to clear the body after the last dose. For GLP-1 drugs, the FDA and EMA recommend stopping the medication well before conception — typically 5 or more half-lives to ensure near-complete elimination.

Based on retatrutide's 6-day half-life, 5 half-lives would equal approximately 30 days. If it follows the same conservative approach as semaglutide, a washout of 6-8 weeks would be expected. But this is speculative — no regulatory body has issued guidance on retatrutide and pregnancy, and the triple-agonist mechanism could warrant a longer or different washout recommendation.

In clinical practice, many providers recommend 4-6 weeks as a general washout for GLP-1 drugs before conception attempts. Given retatrutide's unique receptor profile, some providers may recommend a more conservative timeline. This decision should be made with your healthcare provider.

The "Ozempic Babies" Phenomenon

A widely reported trend — sometimes called "Ozempic babies" — refers to women becoming pregnant unexpectedly while taking GLP-1 receptor agonists, often after years of infertility. This is not a direct pharmacological fertility effect. The mechanism is primarily indirect:

Weight loss restores ovulation. In women with obesity-related anovulation — particularly those with polycystic ovary syndrome (PCOS) — weight loss of 5-10% of body weight can restore regular ovulation and menstrual cycles. GLP-1 drugs achieve this level of weight loss in most participants, and retatrutide achieves it faster than any other drug in the class (24% average weight loss at 48 weeks in Phase 2).

Oral contraceptive interference. GLP-1 receptor agonists slow gastric emptying, which can delay or reduce absorption of oral medications — including birth control pills. Tirzepatide has been shown to affect oral contraceptive absorption. Semaglutide appears to have less effect on oral contraceptive levels. Other GLP-1 drugs (exenatide, liraglutide, dulaglutide) reduced plasma levels of oral contraceptives by up to 45% and delayed absorption by up to 3.5 hours.

Retatrutide's effect on oral contraceptive absorption has not been studied. However, given that it slows gastric emptying through GLP-1 receptor activation, interference with oral contraceptives is plausible.

Nausea and vomiting. GI side effects — particularly during dose escalation — can cause women to lose oral contraceptive doses through vomiting without realizing the impact on contraceptive efficacy. Retatrutide's nausea rates of up to 43% at the 12mg dose make this a meaningful practical concern.

The TRIUMPH Phase 3 trials require women of childbearing potential to use highly effective contraception during the study. Non-oral contraceptive methods — such as IUDs, implants, patches, or condoms — are not affected by delayed gastric emptying and provide more reliable protection for women on GLP-1 drugs.

What We Do Not Know About Retatrutide and Pregnancy

The honest assessment is that the unknowns far outweigh the knowns:

• No human pregnancy data exists for retatrutide — not even inadvertent first-trimester exposures have been reported in the literature
• No animal reproductive toxicity data for retatrutide has been published, though Eli Lilly would have conducted preclinical reproductive studies as part of the IND application
• The interaction between three receptor agonisms during pregnancy is completely unstudied — the GIP/progesterone and glucagon/placenta concerns have only been studied in isolation
• Retatrutide's effect on oral contraceptive absorption has not been tested
• Breastfeeding safety is unknown — it is not known whether retatrutide is excreted in human milk, and no lactation studies have been conducted

Frequently Asked Questions

Sources

• Cesta, C.E., et al. (2024). Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Internal Medicine. DOI: 10.1001/jamainternmed.2023.6045
• Dao, K., et al. (2024). Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study. BMJ Open. PMC11043712
• Vuguin, P.M., et al. (2012). Hypoglycemia, hyperglucagonemia, and fetoplacental defects in glucagon receptor knockout mice: a role for glucagon action in pregnancy maintenance. American Journal of Physiology — Endocrinology and Metabolism. PMC3311287
• Vuguin, P.M., et al. (2006). Ablation of the Glucagon Receptor Gene Increases Fetal Lethality and Produces Alterations in Islet Development and Maturation. Endocrinology. DOI: 10.1210/en.2005-1430
• Bucciarelli, L.M., et al. (2022). Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice. International Journal of Molecular Sciences. PMC9775379
• Tropmann, K., et al. (2018). Incretins modulate progesterone biosynthesis by regulating bone morphogenetic protein activity in rat granulosa cells. Journal of Steroid Biochemistry and Molecular Biology. ScienceDirect
• European Congress of Endocrinology. (2024). GIP receptor is expressed by human cumulus granulosa cells. EA 99 P398
• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Giblin, J., et al. (2026). Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism. DOI: 10.1111/dom.70209
• FDA Prescribing Information: Ozempic (semaglutide), Zepbound (tirzepatide)
• ClinicalTrials.gov: Retatrutide trials

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.

This page discusses pregnancy, fertility, and fetal safety. These are topics where incorrect information can have serious consequences. Do not use anything on this page to make decisions about pregnancy planning, contraception, or medication use during pregnancy or breastfeeding.

Consult a qualified healthcare provider — ideally an obstetrician, maternal-fetal medicine specialist, or reproductive endocrinologist — before making any decisions about GLP-1 medications in the context of pregnancy or fertility. If you are enrolled in a retatrutide clinical trial, consult your trial physician.

The information on this page is drawn from animal studies, observational data on other GLP-1 drugs, and receptor pharmacology research. It does not represent direct evidence about retatrutide in human pregnancy. Animal findings do not always translate to humans.

This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.